D Preiss1, N Rankin2,3, P Welsh2, R R Holman4, A J Kangas5, P Soininen5,6, P Würtz5, M Ala-Korpela5,6,7,8, N Sattar2. 1. Clinical Trial Service and Epidemiological Studies Unit, University of Oxford, Oxford, UK. david.preiss@ndph.ox.ac.uk. 2. BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. 3. Glasgow Polyomics, Joseph Black Building, University of Glasgow, Glasgow, UK. 4. Diabetes Trials Unit, University of Oxford, Oxford, UK. 5. Computational Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland. 6. NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland. 7. Oulu University Hospital, Oulu, Finland. 8. Computational Medicine, School of Social and Community Medicine and the Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Abstract
AIMS: To investigate whether metformin therapy alters circulating aromatic and branched-chain amino acid concentrations, increased levels amino acid concentrations, increased levels of which have been found to predict Type 2 diabetes. METHODS: In the Carotid Atherosclerosis: Metformin for Insulin Resistance (CAMERA) study (NCT00723307), 173 individuals without Type 2 diabetes, but with coronary disease, were randomized to metformin (n=86) or placebo (n=87) for 18 months. Plasma samples, taken every 6 months, were analysed using quantitative nuclear magnetic resonance spectroscopy. Ten metabolites consisting of eight amino acids [three branched-chain (isoleucine, leucine, valine), three aromatic (tyrosine, phenylalanine, histidine) and two other amino acids (alanine, glutamine)], lactate and pyruvate were quantified and analysed using repeated-measures models. On-treatment analyses were conducted to investigate whether amino acid changes were dependent on changes in weight, fat mass or insulin resistance estimated using homeostasis model assessment (HOMA-IR). RESULTS: Tyrosine decreased [-6.1 μmol/l (95% CI -8.5, -3.7); P<0.0001], while alanine [42 umol/l (95% CI 25, 59); P<0.0001] increased in the metformin-treated group compared with the placebo-treated group. Decreases in phenylalanine [-2.0 μmol/l (95% CI -3.6, -0.3); P=0.018] and increases in histidine [2.3 μmol/l (95% CI 0.1, 4.6); P=0.045] were also observed in the metformin group, although these changes were less statistically robust. Changes in these four amino acids were not accounted for by changes in weight, fat mass or HOMA-IR values. Levels of branched-chain amino acids, glutamine, pyruvate and lactate were not altered by metformin therapy. CONCLUSIONS: Metformin therapy results in a sustained and specific pattern of changes in aromatic amino acid and alanine concentrations. These changes are independent of any effects on weight and insulin sensitivity. Any causal link to metformin's unexplained cardiometabolic benefit requires further study.
AIMS: To investigate whether metformin therapy alters circulating aromatic and branched-chain amino acid concentrations, increased levels amino acid concentrations, increased levels of which have been found to predict Type 2 diabetes. METHODS: In the Carotid Atherosclerosis: Metformin for Insulin Resistance (CAMERA) study (NCT00723307), 173 individuals without Type 2 diabetes, but with coronary disease, were randomized to metformin (n=86) or placebo (n=87) for 18 months. Plasma samples, taken every 6 months, were analysed using quantitative nuclear magnetic resonance spectroscopy. Ten metabolites consisting of eight amino acids [three branched-chain (isoleucine, leucine, valine), three aromatic (tyrosine, phenylalanine, histidine) and two other amino acids (alanine, glutamine)], lactate and pyruvate were quantified and analysed using repeated-measures models. On-treatment analyses were conducted to investigate whether amino acid changes were dependent on changes in weight, fat mass or insulin resistance estimated using homeostasis model assessment (HOMA-IR). RESULTS: Tyrosine decreased [-6.1 μmol/l (95% CI -8.5, -3.7); P<0.0001], while alanine [42 umol/l (95% CI 25, 59); P<0.0001] increased in the metformin-treated group compared with the placebo-treated group. Decreases in phenylalanine [-2.0 μmol/l (95% CI -3.6, -0.3); P=0.018] and increases in histidine [2.3 μmol/l (95% CI 0.1, 4.6); P=0.045] were also observed in the metformin group, although these changes were less statistically robust. Changes in these four amino acids were not accounted for by changes in weight, fat mass or HOMA-IR values. Levels of branched-chain amino acids, glutamine, pyruvate and lactate were not altered by metformin therapy. CONCLUSIONS: Metformin therapy results in a sustained and specific pattern of changes in aromatic amino acid and alanine concentrations. These changes are independent of any effects on weight and insulin sensitivity. Any causal link to metformin's unexplained cardiometabolic benefit requires further study.
Authors: Deirdre K Tobias; Patrick R Lawler; Paulo H Harada; Olga V Demler; Paul M Ridker; JoAnn E Manson; Susan Cheng; Samia Mora Journal: Circ Genom Precis Med Date: 2018-04
Authors: Brian D Piccolo; James L Graham; Kimber L Stanhope; Oliver Fiehn; Peter J Havel; Sean H Adams Journal: Am J Physiol Endocrinol Metab Date: 2016-04-19 Impact factor: 4.310
Authors: Stephanie T Chung; Samantha T Matta; Abby G Meyers; Celeste K Cravalho; Alfredo Villalobos-Perez; Joshua M Dawson; Vandhna R Sharma; Maureen L Sampson; James D Otvos; Sheela N Magge Journal: Front Endocrinol (Lausanne) Date: 2021-05-18 Impact factor: 5.555
Authors: Paul Welsh; Naomi Rankin; Qiang Li; Patrick B Mark; Peter Würtz; Mika Ala-Korpela; Michel Marre; Neil Poulter; Pavel Hamet; John Chalmers; Mark Woodward; Naveed Sattar Journal: Diabetologia Date: 2018-05-04 Impact factor: 10.122